Secondary acute myeloid leukemias (AMLs) evolving from an antecedent myeloproliferative
neoplasm (MPN) are characterized by a unique set of cytogenetic and molecular features …

Interferon alfa was first used in the treatment of myeloproliferative neoplasms (MPNs) over
30 years ago. However, its initial use was hampered by its side effect profile and lack of …

Background Polycythaemia vera is a myeloproliferative neoplasm characterised by
excessive proliferation of erythroid, myeloid, and megakaryocytic components in the bone …

Background After discontinuing ruxolitinib, the outcome of patients with myelofibrosis
reportedly has been poor. The authors investigated whether disease characteristics before …

We report the final 2-year end-of-study results from the first clinical trial investigating
combination treatment with ruxolitinib and low-dose pegylated interferon-α2 (PEG-IFNα2) …

Philadelphia-chromosome negative myeloproliferative neoplasms (MPN) are a
heterogeneous group of clonal hematopoietic stem cell disorders characterized by an …

Despite the ongoing development of automated hematology analyzers to optimize complete
blood count results, platelet count still suffers from pre-analytical or analytical pitfalls …

Polycythemia vera (PV) is mainly characterized by elevated blood cell counts, thrombotic as
well as hemorrhagic predisposition, a variety of symptoms, and cumulative risks of fibrotic …

The Essential Thrombocythemia is a Chronic Philadelphia-negative Myeloproliferative
Neoplasm characterized by a survival curve that is only slightly worse than that of age-and …

The myeloproliferative neoplasms (MPNs) are acquired hematological stem cell neoplasms
characterized by driver mutations in JAK2, CALR, or MPL. Additive mutations may appear in …